WebAbstract: Thrombotic thrombocytopenic purpura (TTP) is a rare disease with a mortality rate of over 90% if left untreated. Therapeutic plasma exchange (PEX) is the mainstay of treatment of acquired TTP (aTTP), and with the introduction of PEX, the mortality rate declined dramatically below 20%. Although PEX together with corticosteroids are the ... WebApr 12, 2024 · Die erworbene (sekundäre) thrombotisch-thromboytopenische Purpura (TTP) gehört zum Formenkreis der thrombotischen Mikroangiopathien (TMA ... Wang J, Wu T, Li Z, Tang J, Shen H, Zhu J, Li J, Zhu Q, Qing L (2024) Rituximab as first-line treatment for acquired thrombotic thrombocytopenic purpura. J Int Med Res 45:1253–1260. https ...
Exposure to abatacept or rituximab in the first - ProQuest
WebOn November 28, 2024, the Food and Drug Administration approved Truxima (rituximab-abbs, Celltrion Inc.) as the first biosimilar to Rituxan (rituximab, Genentech Inc.) for patients with CD20 ... WebFeb 1, 2024 · Background: Thrombotic thrombocytopenic purpura (TTP) in pregnancy is a rare but potentially life-threatening condition. Management of severe, refractory TTP during pregnancy is challenging and includes multidisciplinary approach. The prognosis of cases with a variety of hematological and autoimmune diseases, including TTP has changed … irac norms of rbi
Frontiers in pathophysiology and management of thrombotic ...
Web2 days ago · The objective of this study was to analyze and compare the safety and efficacy of caplacizumab vs the standard of care and assess the effect of the concomitant use of rituximab. A retrospective study from the Spanish TTP Registry of patients treated with caplacizumab vs those who did not receive it was conducted. WebFigure 3. Survival analysis. Time to clinical response in patients treated with rituximab + PEX, with or without the addition of caplacizumab (n = 111*). (It should be noted that all patients also received corticosteroids.) *Seven patients were lost to follow-up: 2 patients receiving rituximab and 5 patients receiving rituximab and caplacizumab. WebFeb 11, 2024 · Of these, 10 received rituximab upon initial presentation with TTP and 12 received rituximab at first relapse or afterward. In total, 4 of 22 severe autoimmune … irac norms for npa